Aaron Earles, DO
Interventional Cardiology · Corinth, MSNPI 1740502095
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,300 of the $8,388 with a category attached, or 87.0%. It is spread thinly across 36 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,565 and has fallen 67.7% since, to $829 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MS, where the typical reported total is $7,952.
Across 339 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Abiomed$835
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$737
- AstraZeneca$655
- Boston Scientific$487
- Amgen$381
- plus $4K from 30 others
What the payments were for
- Travel & lodging$1,05113%
- Food & beverage$7,30087%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 24 | $1,691 |
| Abiomed | 26 | $835 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 52 | $737 |
| AstraZeneca | 29 | $655 |
| Boston Scientific | 21 | $487 |
| Amgen | 28 | $381 |
| Merck | 21 | $371 |
| Cvrx, Inc. | 3 | $357 |
| Biotronik Inc. | 8 | $317 |
| Johnson & Johnson | 19 | $288 |
| Novartis | 15 | $212 |
| Boehringer Ingelheim | 12 | $205 |
| Abbott | 5 | $197 |
| Pfizer | 11 | $179 |
| Daiichi Sankyo Inc. | 5 | $178 |
| Esperion Therapeutics, Inc. | 8 | $135 |
| Medtronic(2 entities) | 6 | $132 |
| Cook Medical LLC | 4 | $130 |
| Lexicon Pharmaceuticals, Inc. | 6 | $105 |
| Bard Peripheral Vascular, Inc. | 1 | $103 |
| Avinger Inc. | 2 | $98 |
| Philips North America LLC | 4 | $95 |
| Amarin Pharma, Inc. | 5 | $79 |
| Daxor Corporation | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Bardy Diagnostics, Inc. | 3 | $45 |
| Baxter Healthcare | 3 | $42 |
| GE HealthCare | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Edwards Lifesciences | 1 | $30 |
| Cardiva Medical, Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $21 |
| GSK | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Terumo Medical Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,215
- Barostim Neo System$296
- Impella$238
- Rotablator Rotational Atherectomy System Console Kit$149
- BioMonitor$143
- MitraClip$138
- INJECTAFER$125
- BRILINTA$119
- FARXIGA$110
How this compares
$8,388 in reported general payments places this provider in the 50th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 279 | $217,159 |
| XareltoRivaroxaban | 174 | $161,446 |
| Repatha SureclickEvolocumab | 79 | $62,473 |
| EntrestoSacubitril/Valsartan | 46 | $57,762 |
| BrilintaTicagrelor | 97 | $50,415 |
| JardianceEmpagliflozin | 31 | $37,941 |
| FarxigaDapagliflozin Propanediol | 22 | $25,454 |
| OzempicSemaglutide | 13 | $12,969 |
| Ranolazine ErRanolazine | 134 | $11,268 |
| Praluent PenAlirocumab | 21 | $10,128 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $7,300 |
| VascepaIcosapent Ethyl | 13 | $4,545 |
| Propafenone Hcl | 120 | $4,527 |
| Ezetimibe | 189 | $4,511 |
| Amiodarone Hcl | 206 | $4,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $217,159279 claims |
| Johnson & JohnsonXarelto | $288 | $161,446174 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $655 | $83,169151 claims |
| NovartisEntresto | $212 | $57,76246 claims |
| Boehringer IngelheimJardiance | $205 | $37,94131 claims |
| Novo NordiskOzempic | $19 | $12,96913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Corinth
- Theodore RichardsCorinth$8K
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- John KingColumbus$74K
- Michael CunninghamBiloxi$45K
- Alejandro Lemor FerrandJackson$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.